Jennison Associates LLC increased its holdings in GW Pharmaceuticals PLC- (NASDAQ:GWPH) by 15.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 438,955 shares of the biopharmaceutical company’s stock after buying an additional 57,210 shares during the quarter. Jennison Associates LLC owned about 1.46% of GW Pharmaceuticals PLC- worth $75,671,000 at the end of the most recent reporting period.
A number of other hedge funds have also modified their holdings of the stock. US Bancorp DE grew its holdings in GW Pharmaceuticals PLC- by 0.6% in the 1st quarter. US Bancorp DE now owns 11,683 shares of the biopharmaceutical company’s stock worth $1,969,000 after buying an additional 75 shares in the last quarter. Oppenheimer Asset Management Inc. grew its holdings in GW Pharmaceuticals PLC- by 14.9% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 601 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 78 shares in the last quarter. Brandywine Oak Private Wealth LLC grew its holdings in GW Pharmaceuticals PLC- by 6.0% in the 1st quarter. Brandywine Oak Private Wealth LLC now owns 1,435 shares of the biopharmaceutical company’s stock worth $241,000 after buying an additional 81 shares in the last quarter. Envestnet Asset Management Inc. grew its holdings in GW Pharmaceuticals PLC- by 4.8% in the 2nd quarter. Envestnet Asset Management Inc. now owns 2,014 shares of the biopharmaceutical company’s stock worth $347,000 after buying an additional 92 shares in the last quarter. Finally, YorkBridge Wealth Partners LLC grew its holdings in GW Pharmaceuticals PLC- by 100.0% in the 1st quarter. YorkBridge Wealth Partners LLC now owns 200 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 100 shares in the last quarter. 80.94% of the stock is owned by institutional investors and hedge funds.
In other news, Director William A. Waldegrave sold 3,576 shares of the stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $15.00, for a total transaction of $53,640.00. Following the completion of the sale, the director now owns 3,576 shares in the company, valued at approximately $53,640. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Douglas B. Snyder sold 5,424 shares of the stock in a transaction on Monday, August 19th. The shares were sold at an average price of $13.04, for a total value of $70,728.96. Following the sale, the insider now owns 73,740 shares of the company’s stock, valued at approximately $961,569.60. The disclosure for this sale can be found here. Insiders have sold a total of 284,748 shares of company stock valued at $4,276,763 in the last quarter. Insiders own 3.60% of the company’s stock.
GWPH traded down $1.89 during trading on Friday, reaching $145.46. The stock had a trading volume of 277,951 shares, compared to its average volume of 571,373. The firm has a market capitalization of $4.44 billion, a price-to-earnings ratio of -13.77 and a beta of 2.25. The company has a quick ratio of 7.59, a current ratio of 8.31 and a debt-to-equity ratio of 0.03. GW Pharmaceuticals PLC- has a 1-year low of $90.14 and a 1-year high of $196.00. The stock has a 50 day moving average of $162.91 and a two-hundred day moving average of $166.78.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.78) EPS for the quarter, beating analysts’ consensus estimates of ($1.74) by $0.96. GW Pharmaceuticals PLC- had a negative return on equity of 38.09% and a negative net margin of 101.45%. The company had revenue of $72.04 million during the quarter, compared to the consensus estimate of $37.28 million. During the same quarter in the prior year, the firm earned ($0.25) EPS. The company’s quarterly revenue was up 2096.3% compared to the same quarter last year. On average, research analysts forecast that GW Pharmaceuticals PLC- will post -3.84 EPS for the current fiscal year.
GW Pharmaceuticals PLC- Company Profile
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.
Featured Article: How a Put Option Works
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.